Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry.

[1]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[2]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[3]  R. Morishita,et al.  Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. , 2010, Molecular bioSystems.

[4]  C. Rowe,et al.  Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease , 2010, The Journal of Neuroscience.

[5]  R. Martins,et al.  Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests , 2009, Molecular Psychiatry.

[6]  Johannes Kornhuber,et al.  Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease , 2009, Journal of Neural Transmission.

[7]  H. Masumoto,et al.  Development of a pretreatment method for amyloid beta-protein analysis based on the effect of acetic acid on the dissolution of plasma polypeptides. , 2008, Biomedical chromatography : BMC.

[8]  T. Lanz,et al.  Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Aβ quantification following passive immunization with Aβ antibodies , 2008, Journal of Neuroscience Methods.

[9]  M. Ford,et al.  Qualitative and quantitative characterization of the amyloid β peptide (Aβ) population in biological matrices using an immunoprecipitation–LC/MS assay , 2008, Journal of Neuroscience Methods.

[10]  M. Findeis.  The role of amyloid β peptide 42 in Alzheimer's disease , 2007 .

[11]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[12]  M. Bidlingmaier,et al.  Growth hormone assays: current methodologies and their limitations , 2007, Pituitary.

[13]  D. Holtzman,et al.  Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[14]  D. Pollen,et al.  Familial Alzheimer disease: Decreases in CSF Aβ42 levels precede cognitive decline , 2005, Neurology.

[15]  Frank R. Ervin,et al.  Alzheimer's Disease Aβ Vaccine Reduces Central Nervous System Aβ Levels in a Non-Human Primate, the Caribbean Vervet , 2004 .

[16]  Juan Manuel Maler,et al.  Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau , 2004, Neurobiology of Aging.

[17]  Duane D. Miller,et al.  Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry. , 2004, Analytical chemistry.

[18]  L. Thompson.  Unraveling the secrets of Alzheimer's β-amyloid fibrils , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Enke,et al.  Effect of affinity for droplet surfaces on the fraction of analyte molecules charged during electrospray droplet fission. , 2001, Analytical chemistry.

[20]  Hans Förstl,et al.  Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay* , 1996, The Journal of Biological Chemistry.

[21]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[22]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[23]  D. Selkoe,et al.  Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. , 1991, The American journal of pathology.

[24]  Y. Sakaki,et al.  Complementary DNA for the mouse homolog of the human amyloid beta protein precursor. , 1987, Biochemical and biophysical research communications.

[25]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[26]  L. Vereyken,et al.  A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species. , 2011, Bioanalysis.

[27]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .